Compounds > 2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3

Page last updated: 2024-11-12

2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D3: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	11366080
SCHEMBL ID	12932256
MeSH ID	M0510066

Synonyms (11)

Synonym
SCHEMBL12932256
2-methylene-19-nor-(20s)-1alpha,25-dihydroxyvitamin d3
unii-o9w659of5l
2-methylene-19-nor-(20s)-1.alpha.,25-dihydroxyvitamin d3
1,3-cyclohexanediol, 2-methylene-5-((2e)-2-((1r,3as,7ar)-octahydro-1-((1s)-5-hydroxy-1,5-dimethylhexyl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-, (1r,3r)-
dp-001
O9W659OF5L ,
213250-70-5
2-methylene-19-nor-20-epi-1a,25-dihydroxyvitamin d3
(1r,3r)-5-[(2e)-2-[(3as,7ar)-1-[(2s)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-2-methylidenecyclohexane-1,3-diol
pmid27454349-compound-91

Research Excerpts

Dosage Studied

Excerpt	Relevance	Reference
" Dose-response studies of the comedolytic analogs showed that an increase in epidermal thickness was achieved at a lower dose than that needed to induce comedolysis."	( Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. Ahrens, JM; Clagett-Dame, M; DeLuca, HF; Nieves, NJ; Plum, LA, 2010)	0.36
"Hemodialysis patients were enrolled and dosed with 110, 220, 330, 440, or 550 ng of 2MD orally thrice weekly for 4 weeks."	( Use of 2MD, a Novel Oral Calcitriol Analog, in Hemodialysis Patients with Secondary Hyperparathyroidism. Clagett-Dame, M; Coyne, DW; DeLuca, HF; Pandey, R; Plum, LA; Zella, J, 2016)	0.43

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (16.67)	29.6817
2010's	10 (83.33)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.96 (24.57)
Research Supply Index	2.77 (2.92)
Research Growth Index	4.73 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.96)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (25.00%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (66.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
osteoprotegerin Osteoprotegerin: A secreted member of the TNF receptor superfamily that negatively regulates osteoclastogenesis. It is a soluble decoy receptor of RANK LIGAND that inhibits both CELL DIFFERENTIATION and function of OSTEOCLASTS by inhibiting the interaction between RANK LIGAND and RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B.	2.03	1	0	long-chain fatty acid
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	8.26	12	3	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.05	1	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
phosphorus Phosphorus: A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions.	4.45	1	1	monoatomic phosphorus; nonmetal atom; pnictogen	macronutrient
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.15	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Chronic Kidney Diseases [description not available]	0	2.15	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.49	2	0
Cirrhosis [description not available]	0	2.15	1	0
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	0	2.15	1	0
Renal Insufficiency, Chronic Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)	0	2.15	1	0
Secondary Hyperparathyroidism [description not available]	0	5.41	2	2
Chronic Kidney Failure [description not available]	0	5.41	2	2
Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.	0	5.41	2	2
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	0	5.41	2	2
Acne [description not available]	0	2.05	1	0
Bullous Congenital Ichthyosiform Erythroderma [description not available]	0	2.05	1	0
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	0	2.05	1	0
Low Bone Density [description not available]	0	3.45	1	1
Bone Diseases, Metabolic Diseases that affect the METABOLIC PROCESSES of BONE TISSUE.	0	3.45	1	1
Intraocular Pressure The pressure of the fluids in the eye.	0	2.07	1	0
Milk-Alkali Syndrome [description not available]	0	2.03	1	0
Hypercalcemia Abnormally high level of calcium in the blood.	0	2.03	1	0